Unnatural Products Inc. Raises $45 Million
Unnatural Products Inc., a biotechnology company based in Santa Cruz, California, has successfully raised $45 million in a Series B funding round. This round was led by The Venture Collective, with additional participation from Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures, argenx, and Droia Ventures.
Focus on Macrocyclic Peptide Therapeutics
The company specializes in developing orally-delivered macrocyclic peptides aimed at tackling previously undruggable targets. These macrocyclic peptides are designed to provide the precision of biologics while offering the delivery advantages of small molecules. This innovative approach allows the company to target complex intracellular pathways that have been challenging to address with existing therapeutic modalities.
Cameron Pye, CEO of Unnatural Products, highlighted the potential impact of their technology, stating: "Macrocyclic peptides represent a powerful new therapeutic modality. Our platform unlocks the precision of biologics with the delivery advantages of small molecules."
Strategic Use of Funds
The newly secured funds will be utilized to further develop the company's proprietary drug discovery platform. This will advance Unnatural Products' pipeline of macrocyclic peptide therapeutics, with a focus on addressing historically difficult-to-drug targets.
Recent Developments
In addition to the recent funding, Unnatural Products has entered into a licensing agreement with Novartis. This partnership aims to develop macrocyclic peptide therapeutics for cardiovascular targets that have been historically undruggable. The agreement includes up to $100 million upfront and potential milestones totaling $1.7 billion.
Investors and Leadership
The funding round was prominently led by The Venture Collective, showcasing continued investor confidence in Unnatural Products' innovative approach to drug discovery. The involvement of major investors like Merck Global Health Innovation Fund and Artis Ventures further strengthens the company's position in the biotech industry.
Under the leadership of Cameron Pye, Unnatural Products is poised to make significant strides in the field of biotechnology, particularly in the development of macrocyclic peptides. The company's ongoing efforts aim to unlock new therapeutic pathways and provide solutions for targets that have long been considered out of reach.